GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NGL Fine-Chem Ltd (NSE:NGLFINE) » Definitions » Tax Expense

NGL Fine-Chem (NSE:NGLFINE) Tax Expense : ₹142 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NGL Fine-Chem Tax Expense?

NGL Fine-Chem's tax expense for the months ended in Sep. 2024 was ₹35 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was ₹142 Mil.


NGL Fine-Chem Tax Expense Historical Data

The historical data trend for NGL Fine-Chem's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGL Fine-Chem Tax Expense Chart

NGL Fine-Chem Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.37 208.71 166.99 68.66 131.00

NGL Fine-Chem Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.58 42.96 37.69 25.68 35.18

NGL Fine-Chem Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹142 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGL Fine-Chem  (NSE:NGLFINE) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


NGL Fine-Chem Tax Expense Related Terms

Thank you for viewing the detailed overview of NGL Fine-Chem's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


NGL Fine-Chem Business Description

Traded in Other Exchanges
Address
301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. The company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. Its product includes Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and Finished dosage form, of which maximum revenue is generated from Veterinary APIs. Its geographical segments include India, Europe, Asia Pacific, United States, and Rest of the world. The Group's business activities fall within a single business segment of pharmaceuticals.

NGL Fine-Chem Headlines

No Headlines